RE:RE:Pfizer invests in allogeneic CAR-T therapy companyONCY appears to be closely aligned with Pfizer's oncology acquisition and clinical development program given recent news on Pfizer's CD3 bispecific, ADC, CAR-T and current small molecule portfolio (PARP inhibitor), as several examples.
Consequently, ONCY's acquisition valuation is within the US$10 - US$15 Billion, while some would suggest considerable higher, and that is quite possible as well, given ONCY's expanding bio-platform with pelareorep and the rapidly changing regulatory environment, which increasingly favors ONCY's bio-platform in pelareorep in the application of multiple cancers with unmet treatment needs.